CTI Biopharma Corp is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer benefit to patients and health care providers.
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.
BRIEF: For the fiscal year ended 31 December 2016, CTI BioPharma Corp revenues increased from $16.1M to $57.4M. Net loss applicable to common stockholders decreased 58% to $52M. Revenues reflect License and contract revenue increase from $12.6M to $53.1M, Product sales, net increase of 25% to $4.3M. Lower net loss reflects Research and development decrease of 14% to $62.6M (expense), Other selling , general decrease of 20% to $34.3M (expense).
Recent Price Update
4.26 +0.28 (7.04%)
Apr 25 – Close
NASDAQ real-time data – Disclaimer
Currency in USD
Range 4.20 – 4.52
52 week 3.07 – 6.48
Vol / Avg. 0.00/91,352.00
Mkt cap 122.39M
Inst. own 24%
Nasdaq Stock Risk Assessment
Servier and CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today jointly announced that they agreed to expand their existing license and development collaboration agreement for PIXUVRI® (pixantrone). Under this expanded agreement, Servier will have rights to PIXUVRI in all markets except the US, where CTI BioPharma will retain the commercialization rights. Servier will pay CTI BioPharma €12 million with the potential for CTI BioPharma to receive €76 million in additional sales and regulatory milestone payments as well as royalties on net product sales.
CTIC: 5 years historical graph with some technical indicators
Disclaimer: The views, opinions, and information expressed in this article are those of the authors and do not necessarily reflect the official policy or position of any company stakeholders, financial professionals, or analysts. Examples of analysis performed within this article are only examples. They should not be utilized to make stock portfolio or financial decisions as they are based only on limited and open source information. Assumptions made within the analysis are not reflective of the position of any analysts or financial professionals.